Literature DB >> 6179448

Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

J Laurence, M Coleman, S L Allen, R T Silver, M Pasmantier.   

Abstract

A new multiple-drug protocol consisting of cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine, known as COP-BLAM, was administered to 48 patients with stage III or IV diffuse histiocytic lymphoma. Twenty-four of the 33 previously untreated patients had a complete remission, and eight patients had a partial response. The median survival for all previously untreated patients has not yet been reached at 23 months. Median survival for complte responders has not yet been attained at 26 months, although survival of partial responders is 12.5 months. There were no patients with a complete response who had a central nervous system relapse. The COP-BLAM therapy is an easily administered outpatient program capable of inducing a high frequency of durable complete remissions in advanced diffuse histiocytic lymphoma, a malignancy formerly considered to have a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179448     DOI: 10.7326/0003-4819-97-2-190

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  20 in total

Review 1.  Update on gastric lymphoma.

Authors:  C R Thomas
Journal:  J Natl Med Assoc       Date:  1991-08       Impact factor: 1.798

2.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

3.  [Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

Authors:  B Steinke; J Mau
Journal:  Klin Wochenschr       Date:  1986-05-15

4.  German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.

Authors:  H H Gerhartz; E Thiel; G Brittinger; B Dörken; M Engelhard; W Engert; W Enne; R Fuchs; C H Hagen-Aukamp; D Huhn
Journal:  Blut       Date:  1988-03

5.  Failure of conventional chemotherapy in aggressive lymphomas.

Authors:  D Cunningham; A Hepplestone; N L Gilchrist; J H Dagg; I L Evans; M Soukop
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

6.  Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma.

Authors:  C C Anderson; A H Goldstone; R L Souhami; D C Linch; P G Harper; K A McLennan; M Jones; S J Machin; A M Jelliffe; J C Cawley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 7.  Current approaches to the treatment of advanced-stage non-Hodgkin's lymphoma.

Authors:  J J Rusthoven
Journal:  CMAJ       Date:  1987-01-01       Impact factor: 8.262

8.  [Clinical relevance of glucocorticoid receptors in the treatment of lymphoid neoplasias].

Authors:  U Gehring; A D Ho
Journal:  Klin Wochenschr       Date:  1987-03-16

9.  Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Authors:  K E Landys
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

10.  [IgD paraproteinemia in immunocytoma].

Authors:  G Papakonstantinou; C Eisenhut; H Füessl; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.